Title : Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.

Pub. Date : 2013 Jun

PMID : 23538902






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. XL 888 NRAS proto-oncogene, GTPase Homo sapiens
2 The HSP90 inhibitor XL888 is effective at reversing BRAF inhibitor resistance in melanoma, including that mediated through acquired NRAS mutations. XL 888 NRAS proto-oncogene, GTPase Homo sapiens
3 The present study has investigated the mechanism of action of XL888 in NRAS-mutant melanoma. XL 888 NRAS proto-oncogene, GTPase Homo sapiens
4 In an animal xenograft model of NRAS-mutant melanoma, XL888 treatment led to reduced tumor growth and apoptosis induction. XL 888 NRAS proto-oncogene, GTPase Homo sapiens